Therapeutic potential of interfering with apelin signalling

Drug Discovery Today

Volumn 11, Issue 23-24, 2006, Pages 1100-1106

  Sorli, S Caroline ^a   van den Berghe, Loïc ^a   Masri, Bernard ^a   Knibiehler, Bernard ^a   Audigier, Yves ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; APELIN; APELIN RECEPTOR; APELIN RECEPTOR BLOCKING AGENT; APTAMER; CYTOTOXIC AGENT; ENDOSTATIN; G PROTEIN COUPLED RECEPTOR; MITOGENIC AGENT; RECEPTOR ANTIBODY; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN;

BONE DISEASE; DRUG DELIVERY SYSTEM; ENDOCRINE DISEASE; HEART FAILURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH ULCER; SUBRETINAL NEOVASCULARIZATION; TUMOR VASCULARIZATION; VASCULAR TUMOR;

DRUG DESIGN; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 33751217715     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.10.011     Document Type: Review

References (50)

1. O'Dowd B.F., et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136 (1993) 355-360
2. Devic E., et al. Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mech. Dev. 59 (1996) 129-140
3. Tatemoto K., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251 (1998) 471-476
4. Masri B., et al. Apelin signalling: a promising pathway from cloning to pharmacology. Cell. Signal. 17 (2005) 415-426
5. Audigier, Y. (2006) Apelin Receptor. AfCS-Nat. Mol. Pages doi:10.1038/mp.a000304.01
6. Devic E., et al. Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech. Dev. 84 (1999) 199-203
7. Masri B., et al. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J. 18 (2004) 1909-1911
8. Masri B., et al. The apelin receptor is coupled to gi1 or gi2 protein and is differentially desensitized by apelin fragments. J. Biol. Chem. 281 (2006) 18317-18326
9. Tatemoto K., et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul. Pept. 99 (2001) 87-92
10. Lee D.K., et al. Characterization of apelin, the ligand for the APJ receptor. J. Neurochem. 74 (2000) 34-41
11. Ishida J., et al. Regulatory roles for APJ, a seven-transmembrane receptor related to AT1, in blood pressure in vivo. J. Biol. Chem. 279 (2004) 26274-26279
12. Kasai A., et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem. Biophys. Res. Commun. 325 (2004) 395-400
13. De Mota N., et al. Cloning, pharmacological characterization and brain distribution of the rat apelin receptor. Neuroendocrinology 72 (2000) 400-407
14. O'Carroll A.M., et al. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim. Biophys. Acta 1492 (2000) 72-80
15. Hosoya M., et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275 (2000) 21061-21067
16. Katugampola S.D., et al. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br. J. Pharmacol. 132 (2001) 1255-1260
17. Szokodi I., et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ. Res. 91 (2002) 434-440
18. Kleinz M.J., et al. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul. Pept. 126 (2005) 233-240
19. Chen M.M., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108 (2003) 1432-1439
20. Ashley E.A., et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res. 65 (2005) 73-82
21. Berry M.F., et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110 Suppl. 1 (2004) II187-II193
22. Lee D.K., et al. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol. Sci. 27 (2006) 190-194
23. Wang G., et al. Apelin, a new enteric peptide, localization in the gtogastrointestinal tract, ontogeny, stimulation of gcgastric cell proliferation and of cholecystokinin secretion. Endocrinology 145 (2003) 1342-1348
24. Susaki E., et al. Apelin cells in the rat stomach. Regul. Pept. 129 (2005) 37-41
25. Lambrecht N.W., et al. Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion. Physiol. Genomics 25 (2006) 153-165
26. Sorhede Winzell M., et al. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul. Pept. 131 (2005) 12-17
27. Boucher J., et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146 (2005) 1764-1771
28. Daviaud D., et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J. 20 (2006) 1528-1530
29. Xie H., et al. Apelin and its receptor are expressed in human osteoblasts. Regul. Pept. 134 (2006) 118-125
30. Habata Y., et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim. Biophys. Acta 1452 (1999) 25-35
31. Edinger A.L., et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 72 (1998) 7934-7940
32. Choe H., et al. The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J. Virol. 72 (1998) 6113-6118
33. Cayabyab M., et al. Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J. Virol. 74 (2000) 11972-11976
34. Puffer B.A., et al. Expression and coreceptor function of APJ for primate immunodeficiency viruses. Virology 276 (2000) 435-444
35. Zou M.X., et al. Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBS Lett. 473 (2000) 15-18
36. Saint-Geniez M., et al. Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech. Dev. 110 (2002) 183-186
37. Cox C.M., et al. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev. Biol. 296 (2006) 177-189
38. Inui M., et al. Xapelin and Xmsr are required for cardiovascular development in Xenopus laevis. Dev. Biol. 298 (2006) 188-200
39. Springer M.L. A balancing act: therapeutic approaches for the modulation of angiogenesis. Curr. Opin. Investig. Drugs 7 (2006) 243-250
40. Smith L.E., et al. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35 (1994) 101-111
41. Campochiaro P.A. Retinal and choroidal neovascularization. J. Cell. Physiol. 184 (2000) 301-310
42. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
43. Verheul H.M., et al. Are tumours angiogenesis-dependent?. J. Pathol. 202 (2004) 5-13
44. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
45. Campochiaro P.A. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther. 13 (2006) 559-562
46. Ng E.W., et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5 (2006) 123-132
47. Gerhardt H., et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161 (2003) 1163-1177
48. Klement G., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000) R15-R24
49. Black W.R., and Agner R.C. Tumour regression after endostatin therapy. Nature 391 (1998) 450
50. Boehm T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407